Japanese patients with anaplastic thyroid carcinoma or locally advanced or metastatic medullary thyroid carcinoma
Item
japanese patients with atc (anaplastic thyroid carcinoma) or locally advanced or metastatic mtc (medullary thyroid carcinoma)
boolean
C1556094 (UMLS CUI [1])
C0238461 (UMLS CUI [2])
C0238462 (UMLS CUI [3,1])
C0677984 (UMLS CUI [3,2])
C0238462 (UMLS CUI [4,1])
C0036525 (UMLS CUI [4,2])
ineligible for surgery or radiotherapy with curative intention
Item
not a candidate for surgery or radiotherapy with curative intention
boolean
C1512714 (UMLS CUI [1,1])
C0543467 (UMLS CUI [1,2])
C1276305 (UMLS CUI [1,3])
C1512714 (UMLS CUI [2,1])
C1522449 (UMLS CUI [2,2])
C1276305 (UMLS CUI [2,3])
Histologically or cytologically confirmed atc or mtc
Item
histologically or cytologically confirmed atc or mtc
boolean
C0449575 (UMLS CUI [1,1])
C0238461 (UMLS CUI [1,2])
C1265900 (UMLS CUI [2,1])
C0238461 (UMLS CUI [2,2])
C0449575 (UMLS CUI [3,1])
C0238462 (UMLS CUI [3,2])
C1265900 (UMLS CUI [4,1])
C0238462 (UMLS CUI [4,2])
Clinically evaluable disease according to recist 1.1
Item
measurable or non-measurable disease (but clinically evaluable) according to recist 1.1.
boolean
C1516986 (UMLS CUI [1,1])
C1709926 (UMLS CUI [1,2])
Age
Item
age >= 18 years
boolean
C0001779 (UMLS CUI [1])
adequate bone marrow, liver and renal function to be conducted within 14 days prior to treatment
Item
adequate bone marrow, liver and renal function to be conducted within 14 days prior to treatment
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
Ecog performance status of 0 or 1
Item
eastern cooperative oncology group (ecog) performance status (ps) of 0 or 1
boolean
C1520224 (UMLS CUI [1])
Life expectancy
Item
life expectancy of at least 12 weeks
boolean
C0023671 (UMLS CUI [1])
Histologic subtypes of thyroid cancer other than anaplastic or medullary carcinoma
Item
histologic subtypes of thyroid cancer other than anaplastic or medullary carcinoma
boolean
C0007115 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
C0449560 (UMLS CUI [1,3])
Prior anti-cancer targeted therapy including tyrosine kinase inhibitors, monoclonal antibodies that target vegf or vegf receptors
Item
prior anti-cancer treatment with tyrosine kinase inhibitors, monoclonal antibodies (licensed or investigational) that target vegf or vegf (vascular endothelial growth factor) receptors or other targeted agents
boolean
C0920425 (UMLS CUI [1,1])
C0879484 (UMLS CUI [1,2])
C0920425 (UMLS CUI [2,1])
C2267081 (UMLS CUI [2,2])
C0920425 (UMLS CUI [3,1])
C2917234 (UMLS CUI [3,2])
C0920425 (UMLS CUI [4,1])
C2985566 (UMLS CUI [4,2])
Prior chemotherapy for thyroid cancer
Item
prior chemotherapy for thyroid cancer (only one regimen is allowed)
boolean
C1514457 (UMLS CUI [1,1])
C0007115 (UMLS CUI [1,2])
Major surgery, open biopsy or significant traumatic injury within 30 days prior to enrollment in the study
Item
major surgery, open biopsy, or significant traumatic injury within 30 days prior to enrollment in the study.
boolean
C0332185 (UMLS CUI [1,1])
C0679637 (UMLS CUI [1,2])
C0332185 (UMLS CUI [2,1])
C0184922 (UMLS CUI [2,2])
C0332185 (UMLS CUI [3,1])
C3263723 (UMLS CUI [3,2])
Subjects with tracheal, bronchial or esophageal infiltration with significant risk of bleeding
Item
subjects with tracheal, bronchial or esophageal infiltration with significant risk of bleeding but without having received local treatment prior to enrollment in the study
boolean
C0332448 (UMLS CUI [1,1])
C0040578 (UMLS CUI [1,2])
C3251812 (UMLS CUI [1,3])
C0332448 (UMLS CUI [2,1])
C0006255 (UMLS CUI [2,2])
C3251812 (UMLS CUI [2,3])
C0332448 (UMLS CUI [3,1])
C0014876 (UMLS CUI [3,2])
C3251812 (UMLS CUI [3,3])